##STR1## Novel ester derivatives of carboxylic acid medicaments of formula (I), wherein R--COO--represents the acyloxy residue of a carboxylic acid drug or medicament, n is an integrer from 1 to 3, and R.sub.1 and R.sub.2 are the same or different and are selected from a group consisting of an alkyl, an alkenyl, an aryl, an aralkyl, a cycloalkyl and which group may be unsubstituted or substituted, or R.sub.1 and R.sub.2 together with the N forms a 4-, 5-, 6- or 7-membered heterocyclic ring, which in addition to the nitrogen atom may contain one or two further heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur and which heterocyclic group may be substituted. These compounds are highly biolabile prodrug forms of the corresponding carboxylic acid compounds and are highly susceptible to undergoing enzymatic hydrolysis in vivo whereas they are highly stable in aqueous solution. The novel derivatives are less irritating to mucosa than the parent carboxylic acids and may provide an improved bio-availability of the drugs.
化学药物的新酯衍
生物,其中R--COO--代表
羧酸药物或药剂的酰氧基团,n为1至3的整数,R.sub.1和R.sub.2相同或不同,选自烷基、烯基、芳基、芳基烷基、环烷基的一组,该组可能未取代或取代,或R.sub.1和R.sub.2与N一起形成4、5、6或7元杂环,除氮原子外,还可能含有来自氮、氧和
硫的一到两个进一步的杂原子,该杂环基可能被取代。这些化合物是相应
羧酸化合物的高度
生物可降解的前药形式,极易在体内经受酶
水解,而在
水溶液中则非常稳定。这些新的衍
生物对粘膜的刺激性较原始
羧酸小,并可能提高药物的
生物利用度。